Allegion to Attend 2026 Baird Global Industrial Conference Business Wire Allegion plc (NYSE: ALLE) President and CEO John H. Stone as well as Senior Vice President and Chief Financial Officer Mike Wagnes will discuss the company’s long-term strategy at the 2026 Baird Global Industrial Conference on Thursday, Nov. 12. The conference will be held in Chicago. A live listen-only webcast will be accessible via Allegion’s [...]
AngloGold Ashanti Q3 30 September 2026 Earnings Release and Dividend Declaration Business Wire Q3 2026 EBITDA*(5) +12% to $1.57bn • Q3 2026 free cash flow* $722m • YTD free cash flow* $2.6bn • Q3 2026 interim dividend of $361m, or 71 cps • Full-year 2026 guidance(6) reaffirmed • Net cash*(5) expands to $1.26bn • Organic growth plan charted
Titan SA: Nine-Month 2026 Results Business Wire Strong nine-month sales expansion of 9%, attributed to growth in all regions and improved profitability in Greece, Southeastern Europe and the Eastern Mediterranean
SES Delivers Solid 9 Months & Q3 2026 Results and Reiterates Full-Year Outlook November 5, 2026 SES S.A. announces financial results for the nine and three months ended September 30, 2026. YTD 2026 Performance (€ million) YTD 2026 as reported (1) YTD 2025 as reported (1)(5) ∆ At constant FX (2) YTD 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.16 1.11 1.11 [...]
Arm Holdings plc Reports Results for the Second Quarter of the Fiscal Year Ending 2027 November 4, 2026 Arm Holdings plc (NASDAQ: ARM), the company that is building the future of computing, has today published a letter to its shareholders containing the company’s results for its second quarter of fiscal year 2027, which ended Sept. 30, 2026. The letter is available on its investor relations website (https://investors.arm.com/financials/quarterly-annual-results). The shareholder letter will also be [...]
IFF Reports Third Quarter 2026 Results November 3, 2026 Delivered Strong Sales, Profit and Cash Flow Performance in Third Quarter 2026 Raising Low-End of Full Year 2026 Financial Guidance Ranges Recently Completed $500M Share Repurchase Authorization Food Ingredients Divestiture Progressing Well and On Track to Close by End of Second Quarter 2027
Alkermes to Present at Upcoming Investor Conferences November 3, 2026 Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2026 Healthcare Conference Date/Time: Fireside chat on Tuesday, Nov. 10, 2026 at 10:40 a.m. ET (3:40 p.m. GMT) Jefferies Global Healthcare Conference in London Date/Time: Fireside chat on Wednesday, Nov. 18, 2026 at 11:30 a.m. ET (4:30 p.m. GMT) [...]
Alkermes plc Reports Third Quarter 2026 Financial Results November 3, 2026 Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended September 30, 2026. To view the detailed third quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) today, to discuss [...]
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights November 3, 2026 Final NDA submission nearing completion and will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share COMP360 expected to fit seamlessly into current treatment infrastructure Late-stage PTSD trial ongoing Strong cash position of $444 million at the end of third quarter, providing cash well beyond launch and into 2028 Compass management will host a call on November 3 at 8:00 am ET
ReNew Announces Results for the Second Quarter of Fiscal 2027 (Q2 FY27) and First Half of Fiscal 2027 (H1 FY27), both ended September 30, 2026 November 2, 2026 ReNew Energy Global Plc (“ReNew” or “the Company”) (Nasdaq: RNW, RNWWW), a leading decarbonization solutions company, today announced its unaudited consolidated IFRS results for Q2 FY27 and H1 FY27. Operating Highlights: As of September 30, 2026, the Company’s portfolio consisted of ~20.5 GW (including 1.7 GW/6.2 GWh of BESS). Additionally, ReNew has 6.4 GW of [...]